摘要
目的探讨雷贝拉唑和奥美拉唑治疗幽门螺杆菌相关性十二指肠球溃疡患者的疗效。方法选取2020年9月至2023年9月本院幽门螺杆菌相关性十二指肠球溃疡患者100例,随机分为2组,每组50例,对照组服用奥美拉唑治疗,研究组服用雷贝拉唑治疗。比较2组临床疗效、溃疡愈合率、幽门螺杆菌转阴率,以及治疗前后症状积分、H^(+)-K^(+)-ATP酶活性、胃内pH值、炎性因子水平[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子(TNF-α)、白介素-6(IL-6)]变化情况,并观察不良反应发生情况。结果2组间治疗疗效对比差异无统计学意义(P>0.05);研究组溃疡愈合率、幽门螺杆菌转阴率高于对照组(P<0.05);2组治疗后症状积分均有所下降(P<0.05),与对照组比较,研究组治疗后的症状积分更低(P<0.05);治疗后研究组H^(+)-K^(+)-ATP酶活性低于治疗前及对照组,胃内pH值高于治疗前及对照组(P<0.05)。2组治疗后的hs-CRP、TNF-α、IL-6水平均有所降低(P<0.05),与对照组比较,研究组治疗后的hs-CRP、TNF-α、IL-6水平均更低(P<0.05);2组间口干、皮疹、头痛、腹泻、头晕合计不良反应发生率比较,差异无统计学意义(P>0.05)。结论与服用奥美拉唑治疗比较,幽门螺杆菌相关性十二指肠球溃疡患者服用雷贝拉唑治疗,可降低H^(+)-K^(+)-ATP酶活性,升高胃内pH值,对异常炎性因子水平给予更好的纠正,加速改善患者病症,有效性、安全性均更高,值得临床优先应用。
Objective To investigate the clinical efficacy of rabeprazole versus omeprazole in the treatment of Helicobacter pylori(Hp)-induced duodenal ulcer.Methods One hundred patients with Hp-induced duodenal ulcer treated in our hospital from September 2020 to September 2023 were randomly assigned in 1:1 ratio to omeprazole(control group)or rabeprazole(study group).The aim was to compare ulcer healing rate,Hp negative rate,symptoms scores,H^(+)-K^(+)-ATPase activity,intragastric pH,inflammatory factor level,incidence of adverse reactions.The curative effect was assessed.Results None of the curative efficacy differed significantly between groups(P>0.05).The ulcer healing rate and Hp negative rate were significantly higher in the study group than in the control group(P<0.05).After treatment,the disorder symptoms scores in the both groups were significantly decreased(P<0.05),which decreased notably in the study group compared to the control group(P<0.05).After treatment,significantly decreased H^(+)-K^(+)-ATPase activity,and increased intragastric pH were detected in the study group than those before treatment(all P<0.05),with between groups significant differences(all P<0.05).The high-sensitivity C-reactive protein(hs-CRP),tumour necrosis factor alpha(TNF-α),interleukin 6(IL-6)in the both groups were significantly decreased(P<0.05),the decrease in the study group was more common than the control group(P<0.05).There were no between groups significant differences in the incidence of adverse reactions including dry mouth,rash,headache,diarrhea,dizziness(P>0.05).Conclusion Rabeprazole has better therapeutic effect compared to omeprazole in patients with Hp-induced duodenal ulcer,it can reduce H^(+)-K^(+)-ATPase activity,increase intragastric pH,better correct abnormal inflammatory factor levels,rapidly improve disorder symptoms,and with higher effectiveness and safety,which is worthy of clinical priority.
作者
谭海成
焦云涛
张立宏
TAN Haicheng;JIAO Yuntao;ZHANG Lihong(Department of Gastroenterology,Shunyi Hospital,Beijing Traditional Chinese Medicine Hospital,Beijing 101300,China)
出处
《河北医药》
CAS
2024年第18期2788-2791,共4页
Hebei Medical Journal
基金
北京中医医院顺义医院院级基金(编号:SYYJLC-202105)。
